Jennifer Williams, LICSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 508 Bethel St, Clover, SC 29710 Phone: 803-675-8227 |
Rosa Maria Li Vigni, LISW-CP Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1120 Amesbury Ct, Apt. 207, Clover, SC 29710 Phone: 917-751-3260 |
Miss Lucretia Beanica Tillman, LCSWA Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1020 Wylie Springs Cir Apt 17-201, Clover, SC 29710 Phone: 980-328-6234 |
News Archive
Two U.S. Department of Health and Human Services agencies will collaborate in the most comprehensive study to date of prescription medications used to treat attention deficit hyperactivity disorder (ADHD) and the potential for increased risk of heart attack, stroke or other cardiovascular problems.
The Fred Hutch Bone Marrow Transplant Program at Seattle Cancer Care Alliance has earned recognition by the Center for International Blood and Marrow Transplant Research for outperforming its expected one-year survival rates for allogeneic transplant patients - those who receive donated adult blood-forming stem cells.
A practice-changing study, NRG Oncology clinical trial NRG-RTOG 9802, has demonstrated, for the first time, a survival benefit of adjuvant chemotherapy following radiotherapy over radiotherapy alone in certain subgroups of patients with high-risk, low-grade glioma (WHO classification: LGG, grade II), a type of brain tumor that originates from glial cells.
In 2012, the public healthcare sector in Australia was more than twice the size of the private healthcare sector in terms of hospital beds and total hospital expenditure. While private healthcare and other small to medium medical facilities do provide facilities management opportunities, it is mostly to small and medium FM companies. The larger and well-established FM providers will mostly come into play with the successful implementation of public private partnerships model in the healthcare sector.
CPEX Pharmaceuticals Inc. today reported preliminary results related to its Phase 2a proof-of-concept clinical trial of the Company's nasal insulin product, Nasulin™. The study was designed to evaluate the efficacy and safety of Nasulin versus placebo over a 6-week treatment period in subjects with Type 2 diabetes who were being treated with basal insulin and oral anti-diabetes agents.
› Verified 3 days ago